Skip to content
Open access · CC-BY via OpenAlex

Rapamycin for the aging skin

Mikhail V. Blagosklonny

Aging · 2019 · ▲ 14 citations

Abstract

In 2007, I filed a patent application claiming that topical mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (e.g., in the form of a cream or ointment) https://patents.google.com/patent/WO2008022256A2/encould be used to prevent and treat skin aging.Potential indications include various types of age-related spots, wrinkles, photo-aged skin, and other age-related skin conditions.The patent was not granted, nor were cosmetic companies interested in pursuing this avenue of product development.Cell senescence(definition) has traditionally been seen as growth arrest.It seemed weird that rapamycin, a drug that inhibits growth, could inhibit cellular senescence.Nonetheless, it works because, actually, senescence is a continuation of growth when true growth is impossible [1]; in other words, senescence is "twisted" growth [2].In an exciting 'twist', these claims were recently confirmed in a clinical trial by Chung et al. [3], which I will discuss later.Even in 2007, the idea of using rapamycin topically was not novel [4,5].(What was novel in my application was the idea of using topical rapamycin as an anti-aging drug for the aging skin [1]).By now, there have been dozens of papers describing the therapeutic use of rapamycin (Sirolimus) in patients with such skin diseases as lymphatic malformations, vascular anomalies, Facial Angiofibroma and psoriasis [6][7][8][9][10][11][12][13].These diseases were treated in children and young adults.In one study, topical rapamycin at low doses (0.003-0.015%) decreased facial angiofibromas in young adults.There was no systemic absorption of rapamycin (blood levels were <1.0 ng/mL) [13].Returning to cellular senescence, signaling in the mTOR (Target of Rapamycin) pathway drives growth of cellular mass and sustains cell cycle progression.Cells grow and divide, balancing growth.But when the cell cycle is suddenly blocked by p16 or p21, mTOR drives growth-like conversion from reversible arrest (quiescence) to senescence [2,14].In short, mTOR drives geroconversion [15].Rapamycin and its analogs, as well as pan-mTOR inhibitors, suppress geroconversion, thereby maintaining cells in a young healthy state.Moreover, these drugs prevent loss of cells' proliferative potential, which is considered a strict definition of senescence [2,15].Geroconversion in stem cells leads to stem cells depletion [16,17].mTORdriven hypertrophy can be followed by atrophy at the end stages.Cellular hyperfunction eventually leads to cellular exhaustion and secondary functional decline [1].www.aging-us.comAGING 2019, Vol.11, No. 24 Rapamycin for the aging skin

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.18632/aging.102664
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Blagosklonny, M.V. (2019). Rapamycin for the aging skin. <em>Aging</em>. https://doi.org/10.18632/aging.102664
Vancouver
Blagosklonny MV. Rapamycin for the aging skin. Aging. 2019. doi:10.18632/aging.102664.
BibTeX
@article{mikhail2019Rapamy, title = {Rapamycin for the aging skin}, author = {Mikhail V. Blagosklonny}, journal = {Aging}, year = {2019}, doi = {10.18632/aging.102664}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings